The immune system's influence on the brain and behavior has been extensively studied, revealing pathways through which immune responses can affect brain function, including neurotransmitter metabolism, neuroendocrine function, synaptic plasticity, and neurocircuits regulating mood, motivation, anxiety, and alarm. Pro-inflammatory cytokines, such as IL-1, IL-6, and TNF-alpha, can access the central nervous system (CNS) and interact with cytokine networks in the brain, leading to behavioral symptoms like depression, anxiety, fatigue, and cognitive dysfunction, which overlap with those of neuropsychiatric disorders. Key pathways include cytokine signaling molecules like p38 MAPK and NF-kB, indoleamine 2,3-dioxygenase (IDO) and its metabolites, and neurotransmitters such as serotonin, dopamine, and glutamate. Vulnerability factors like aging, obesity, and chronic stress can exacerbate immune-brain signaling, contributing to neuropsychiatric diseases. Understanding these mechanisms provides therapeutic targets and strategies for preventing neuropsychiatric disorders. Sickness behavior, characterized by depressive-like symptoms, is mediated by pro-inflammatory cytokines and can be reversed by cytokine antagonists. In clinical settings, elevated inflammatory markers are associated with depression, and cytokine therapy can induce mood and cognitive symptoms, which may respond to antidepressants. Cytokine signaling can access the brain through various pathways, including the blood-brain barrier, neural pathways, and cellular entry. The brain's cytokine network involves neurons, microglia, and astrocytes, which produce cytokines and amplify signals. Cytokines affect neurotransmitter systems, neuroendocrine function, and neural plasticity, contributing to depression and other neuropsychiatric disorders. Chronic inflammation, from pathophysiological or non-pathological conditions like aging and obesity, can exacerbate these effects. T cell dysfunction, including reduced regulatory T cells and increased Th17 activity, is linked to depression. Inflammation in aging and obesity is associated with chronic low-grade inflammation, increased oxidative stress, and microglial activation, contributing to neuropsychiatric symptoms. Targeting cytokines and their pathways offers potential therapeutic strategies for neuropsychiatric disorders.The immune system's influence on the brain and behavior has been extensively studied, revealing pathways through which immune responses can affect brain function, including neurotransmitter metabolism, neuroendocrine function, synaptic plasticity, and neurocircuits regulating mood, motivation, anxiety, and alarm. Pro-inflammatory cytokines, such as IL-1, IL-6, and TNF-alpha, can access the central nervous system (CNS) and interact with cytokine networks in the brain, leading to behavioral symptoms like depression, anxiety, fatigue, and cognitive dysfunction, which overlap with those of neuropsychiatric disorders. Key pathways include cytokine signaling molecules like p38 MAPK and NF-kB, indoleamine 2,3-dioxygenase (IDO) and its metabolites, and neurotransmitters such as serotonin, dopamine, and glutamate. Vulnerability factors like aging, obesity, and chronic stress can exacerbate immune-brain signaling, contributing to neuropsychiatric diseases. Understanding these mechanisms provides therapeutic targets and strategies for preventing neuropsychiatric disorders. Sickness behavior, characterized by depressive-like symptoms, is mediated by pro-inflammatory cytokines and can be reversed by cytokine antagonists. In clinical settings, elevated inflammatory markers are associated with depression, and cytokine therapy can induce mood and cognitive symptoms, which may respond to antidepressants. Cytokine signaling can access the brain through various pathways, including the blood-brain barrier, neural pathways, and cellular entry. The brain's cytokine network involves neurons, microglia, and astrocytes, which produce cytokines and amplify signals. Cytokines affect neurotransmitter systems, neuroendocrine function, and neural plasticity, contributing to depression and other neuropsychiatric disorders. Chronic inflammation, from pathophysiological or non-pathological conditions like aging and obesity, can exacerbate these effects. T cell dysfunction, including reduced regulatory T cells and increased Th17 activity, is linked to depression. Inflammation in aging and obesity is associated with chronic low-grade inflammation, increased oxidative stress, and microglial activation, contributing to neuropsychiatric symptoms. Targeting cytokines and their pathways offers potential therapeutic strategies for neuropsychiatric disorders.